Panagora Asset Management Inc. Acquires Shares of 794,329 Coherus Oncology, Inc. $CHRS

Panagora Asset Management Inc. acquired a new stake in shares of Coherus Oncology, Inc. (NASDAQ:CHRS) during the second quarter, Holdings Channel.com reports. The fund acquired 794,329 shares of the biotechnology company’s stock, valued at approximately $581,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC acquired a new stake in Coherus Oncology during the 2nd quarter valued at $33,000. Ieq Capital LLC boosted its position in Coherus Oncology by 52.5% in the 1st quarter. Ieq Capital LLC now owns 75,020 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 25,837 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Coherus Oncology by 65.3% during the second quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 36,257 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Coherus Oncology during the first quarter valued at about $77,000. Finally, Deutsche Bank AG increased its position in shares of Coherus Oncology by 198.9% during the first quarter. Deutsche Bank AG now owns 117,983 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 78,508 shares during the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus Oncology Trading Down 2.4%

Shares of NASDAQ CHRS opened at $1.20 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42. The stock’s 50 day moving average price is $1.50 and its two-hundred day moving average price is $1.17. Coherus Oncology, Inc. has a 52-week low of $0.71 and a 52-week high of $1.89. The stock has a market capitalization of $145.04 million, a P/E ratio of 0.90 and a beta of 0.95.

Coherus Oncology (NASDAQ:CHRS) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $11.57 million during the quarter, compared to the consensus estimate of $13.41 million. On average, analysts anticipate that Coherus Oncology, Inc. will post -1.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CHRS shares. Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a report on Wednesday, October 8th. Wall Street Zen upgraded Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Maxim Group raised shares of Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Thursday, September 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Coherus Oncology presently has a consensus rating of “Hold” and a consensus price target of $4.02.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.